Fact Source: Financial Supervisory Service DART / 2025-10-28
Disclosure Type: Preliminary Earnings Release (Consolidated Financial Statement Base)
💡 3-Second Summary
Samsung Biologics released its preliminary financial results for Q3 2025, showing that consolidated operating profit increased by 115.27% YoY to KRW 728.8B, and revenue increased by 39.86% YoY to KRW 1.66T.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Earnings Period: Q3 2025 (Current Quarter: 2025-07-01 ~ 2025-09-30)
- Revenue (Sales):
- Q3 2025: KRW 1,660,221 million (approx. KRW 1.66T; up 28.71% QoQ, up 39.86% YoY)
- Cumulative (Jan-Sep): KRW 4,248,399 million (approx. KRW 4.25T; up 29.10% YoY)
- Operating Profit:
- Q3 2025: KRW 728,848 million (approx. KRW 728.8B; up 53.25% QoQ, up 115.27% YoY)
- Cumulative (Jan-Sep): KRW 1,691,137 million (approx. KRW 1.69T; up 70.07% YoY)
- Net Profit:
- Q3 2025: KRW 574,460 million (approx. KRW 574.4B; up 77.09% QoQ, up 117.21% YoY)
- Cumulative (Jan-Sep): KRW 1,274,399 million (approx. KRW 1.27T; up 67.28% YoY)
- Note: This specific filing does not explain the concrete causes behind the earnings variations. Figures are preliminary and subject to change based on final external audit results.
📈 2. [Expert Insight: What This Disclosure Means for Investors]
This disclosure presents Samsung Biologics’ preliminary financial metrics for Q3 2025, indicating that revenue, operating profit, and net profit all increased compared to both the same period last year and the previous quarter.
The primary figures for market participants to register are the growth rates across each section. The YoY increases in quarterly operating profit (115.27%) and net profit (117.21%) outpaced the revenue growth rate (39.86%). Additionally, on a cumulative nine-month basis, revenue grew by 29.10%, operating profit by 70.07%, and net profit by 67.28%. Because this filing does not state the explicit operational causes behind these changes, market participants should focus on the verified numerical variations.
In conclusion, an increase in performance metrics compared to the previous quarter and the same period last year is verified through this preliminary report. Since these figures are preliminary and remain subject to change depending on the external audit, investors should evaluate these metrics alongside the final audited results when they are released.
📝 Editor’s Comment (by K-STOCK Editor)
Samsung Biologics’ preliminary earnings report for Q3 2025 demonstrates growth across all major indicators, including revenue, operating profit, and net profit, relative to the prior quarter and the same period last year. Notably, the quarterly operating profit rose by 115.27% YoY to reach KRW 728.8B. However, because the filing does not detail whether these results met broader market expectations or outline the specific factors behind the performance growth, the underlying causes cannot be determined from this text. Given that these preliminary figures are subject to final audit adjustments, market participants are advised to follow the disclosure cycle until the audited financials are officially finalized.
📢 Disclaimer and Source Information
Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance inquiries or copyright-related requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
